Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 740 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Migraine Headaches Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Two Rizatriptan Prescribing Portions for Treatment of Migraine

NCT00397254
View directory record Official record
Conditions
Migraine
Interventions
rizatriptan
Drug
Lead sponsor
Clinvest
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
10
States / cities
Diamond Bar, California • San Francisco, California • Oviedo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Sep 11, 2026, 4:15 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06417775
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo for Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 11, 2026, 4:15 PM EDT
Withdrawn Phase 2 Interventional

Single vs Multi-fraction SRS Patients on Immunotherapy

NCT04427228
View directory record Official record
Conditions
Brain Cancer, Brain Metastases
Interventions
Radiosurgery Single Treatment, Radiosurgery Three Treatments
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 11, 2026, 4:15 PM EDT
Terminated No phase listed Observational

Frovatriptan and Menstrual Migraine

NCT01114711
View directory record Official record
Conditions
Frovatriptan, Menstrual Migraine
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Not applicable Interventional

A Pilot Study of Creative Arts Interventions for Neurology Inpatients

NCT03520777
View directory record Official record
Conditions
Epilepsy, Migraine
Interventions
Art Intervention
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Not applicable Interventional

A Preliminary Investigation of the Efficacy of Aromatherapy in Reducing Discomfort in Youth With Chronic Headache

NCT02440997
View directory record Official record
Conditions
Chronic Headache, Migraine Headache, Headache
Interventions
aromatherapy, foot bath
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 11, 2026, 4:15 PM EDT
Completed No phase listed Observational Results available

A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

NCT01749410
View directory record Official record
Conditions
Chronic Migraine, Headaches
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

NCT00875784
View directory record Official record
Conditions
Migraine Disorders
Interventions
TREXIMA™, IMITREX® (4mg), IMITREX® (6mg), IMITREX Tablet 100mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Loxapine in Migraine (in Clinic)

NCT00489476
View directory record Official record
Conditions
Migraine
Interventions
Staccato Loxapine, Staccato Placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Wellesley Hills, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 11, 2026, 4:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)

NCT02964741
View directory record Official record
Conditions
Migraine
Interventions
Active Comparator, Sham Comparator
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 11, 2026, 4:15 PM EDT
Not listed No phase listed Observational

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

NCT06154070
View directory record Official record
Conditions
Migraine Disorders
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
Ki Health Partners. LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Results available

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

NCT02542605
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, PACAP-38 Challenge Agent
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Clinical Decision Support for Patient Migraine Management

NCT03706794
View directory record Official record
Conditions
Migraine
Interventions
Clinical Decision Support Tool, Headache Education
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura

NCT00959751
View directory record Official record
Conditions
Migraine Without Aura
Interventions
NXN-188, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
St. Petersburg, Florida • Atlanta, Georgia • Mount Vernon, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

A Research Study to Examine the Difference Between Local Anesthetics Alone and Local Anesthetics Plus Steroids in the Treatment of Chronic Headache

NCT00203294
View directory record Official record
Conditions
Migraine
Interventions
lidocaine, bupivicaine and saline, lidocaine plus bupivicaine plus triamcinolone (steroid)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 11, 2026, 4:15 PM EDT
Active, not recruiting Phase 4 Interventional

Nerivio Efficacy Under High-Frequency Use

NCT07336056
View directory record Official record
Conditions
Migraine
Interventions
Nerivio (REN device)
Device
Lead sponsor
Theranica
Industry
Eligibility
8 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 11, 2026, 4:15 PM EDT
Completed No phase listed Observational

High School Start Time and Teen Migraine Frequency

NCT03766412
View directory record Official record
Conditions
Migraine
Interventions
High School start time
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 11, 2026, 4:15 PM EDT
Completed No phase listed Observational Results available

Acute Treatment of Migraine in Pre-Adolescents: Real-World Analysis of Remote Electrical Neuromodulation (REN)

NCT06138756
View directory record Official record
Conditions
Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
6 Years to 12 Years
Enrollment
293 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

NCT03939312
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
113
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 11, 2026, 4:15 PM EDT
Recruiting Phase 3 Interventional

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
124
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 11, 2026, 4:15 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Low-dose Naltrexone in Chronic Migraine With Fibromyalgia

NCT05536050
View directory record Official record
Conditions
Chronic Migraine, Fibromyalgia, New Daily Persistent Headache
Interventions
Migraine diary and Questionnaires
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 11, 2026, 4:15 PM EDT
Completed No phase listed Observational Results available

Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs

NCT00386880
View directory record Official record
Conditions
Migraine
Interventions
Sounds
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 11, 2026, 4:15 PM EDT
Recruiting Phase 4 Interventional

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

NCT07301008
View directory record Official record
Conditions
Migraine, Trigger Induced Migraine
Interventions
Rimegepant 75 MG
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
McLean, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Not applicable Interventional

CBT Depression Intervention for Co-Occurring Chronic Headache

NCT02870725
View directory record Official record
Conditions
Depression, Headaches Chronic, Migraine Disorders
Interventions
CBT Individual Psychotherapy
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Athens, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 11, 2026, 4:15 PM EDT